echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Front Oncol: Hefei Research Institute of the Chinese Academy of Sciences, etc. revealed that AURKA rs2273535 T-A polymorphism is associated with an increased risk of cancer.

    Front Oncol: Hefei Research Institute of the Chinese Academy of Sciences, etc. revealed that AURKA rs2273535 T-A polymorphism is associated with an increased risk of cancer.

    • Last Update: 2020-07-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    !---- Recently, the Jinfu team of the Hefei Institute of Physical Sciences of the Chinese Academy of Sciences demonstrated that aurora kinase AURKA rs2273535 T-gt;A polymorphism was associated with an overall increase in cancer risk, especially breast cancer.research on AURKA rs2273535 T?gt; A Polymorphism Associated With Cancer Risk: A System With With Meta-Analysis, published in Frontiers in Oncology.Aurora kinase A (AURKA) is a cell cycle regulation of serine/suine kinase that promotes the cell cycle process.it plays an important role in regulating the transition of cells from the G2 phase of silk division to The M. The association between Polymorphism and cancer risk in aAURKA rs2273535 T-gt;A polymorphism has been studied, but the results have been mixed.study conducted a comprehensive analysis of 36 "case-control studies", including 22,884 cancer cases and 30,497 healthy controls.calculate the advantage ratio and 95% confidence interval to determine their correlation. theanalysis showed that aurKA rs2273535 T-gt;A polymorphism increased the overall risk of cancer, and the results of the three model parameters were: pure conjugon model OR.17, 95% CI, 1.04-1 .33; recessive model OR.1.15, 95% CI- 1.05-1.25; alleling model OR is 1.07, 95% CI is 1.02-1.13.stratified analysis by type of cancer further suggests that this polymorphism is associated with an increased risk of breast cancer.the study was completed in collaboration with Wang Meng, an associate researcher at the Hefei Institute of Stem Cells and Regenerative Medicine of the Chinese Academy of Sciences, and Zhu Meiling, a doctor at Xinhua Hospital affiliated with Shanghai Jiaotong University School of Medicine.research work has been supported by the National Natural Science Foundation of China, the Foundation of the President of Hefei Research Institute (Spark Fund) and so on..
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.